Double-Dose transplant strategy shows promise for myeloma patients

NCT ID NCT01241708

Completed Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a two-step (tandem) stem cell transplant in 148 people with multiple myeloma. Patients received high-dose melphalan chemotherapy, followed by a second transplant with melphalan plus bortezomib (Velcade). The goal was to see if this approach could delay cancer progression. The trial is complete, and results help guide future treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Melphalan and Bortezomib (Velcade)
What this could lead to: If successful, this approach could extend the time patients with multiple myeloma live without their cancer worsening.
What could go wrong: This is a completed phase 3 trial, but results may not apply to all patients. High-dose chemotherapy carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTO STEM CELL TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTO STEM CELL TRANSPLANT MULTIPLE MYELOMA

Contacts and locations

Locations

John Theurer Cancer Center @ Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.